SB05 PC is Approved to Conduct Phase III Clinical Trial for Pancreatic Cancer by ANSM
We are excited to announce that SynCore Biotechnology receives Investigational New Drug (IND) clearance of [...]
SynCore Bio SB04 Dry-AMD in Phase II/III trial
SB04 is an invasive treatment for dry Age-related Macular Degeneration which is available for patient [...]
SynCore Biotechnology Receives Investigational New Drug (IND) Clearance of SB05 PC by the Taiwan Food and Drug Administration (TFDA) to Conduct a Phase III Clinical Trial for the Treatment of Metastatic Adenocarcinoma of the Pancreas
Investigational New Drug (IND) clearance from TFDA represents a key milestone in SynCore’s new drug [...]
SynCore Bio to present the Phase I study of SB01 at ASCO 2017
SynCore Biotechnology Co., Ltd. (SynCore) is selected to present the Phase I study of SB01 [...]
SynCore Biotechnology Receives Investigational New Drug (IND) Clearance of SB05 PC by the US Food and Drug Administration (FDA) to Conduct a Phase III Clinical Trial for the Treatment of Metastatic Adenocarcinoma of the Pancreas
• Investigational New Drug (IND) clearance from US FDA represents a key milestone in SynCore’s [...]
SynCoreBio Signs Contract with Swiss Company Y-YBar To Jointly Develop Precision Instruments for the Diagnosis of Eye Diseases
SynCore Biotechnology Co. Ltd. (4192) signed a global contract today (11/8) with Swiss optical instruments [...]
SynCoreBio significance progress in the negotiations of cooperation strategy. Breakthrough the predominance and maximizing the value of technology platform!
SynCoreBio together with its strategic partner German company Medigene (MG) announced today (December 17 2015) for [...]